Elevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell

MT Newswires Live

Mar 20, 2025

Elevation Oncology (ELEV) said Thursday it is dropping its development of EO-3021, an antibody-drug conjugate for the potential treatment of advanced, unresectable, or metastatic gastric and gastroesophageal junction cancers.

The decision to discontinue clinical development of EO-3021 was based on data from the dose escalation and expansion stages of a phase 1 trial which "deeply disappointed" the company, said Joseph Ferra, president and chief executive officer.

The company said it will continue to advance EO-1022, a potential treatment for patients with HER3-expressing solid breast cancer tumors while beginning a process to evaluate strategic options to maximize shareholder value.

Shares of the company fell more than 24% in recent premarket activity.

Price: 0.3489, Change: -0.122, Percent Change: -24.69

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2520456980"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520456980\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2520456980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-20 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520456980","market":"fut","top_or_hot":-1,"title":"Elevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Elevation Oncology (ELEV) said Thursday it is dropping its development of EO-3021, an antibody-drug conjugate for the potential treatment of advanced, unresectable, or metastatic gastric and gastroesophageal junction cancers.</p><p>The decision to discontinue clinical development of EO-3021 was based on data from the dose escalation and expansion stages of a phase 1 trial which \"deeply disappointed\" the company, said Joseph Ferra, president and chief executive officer.</p><p>The company said it will continue to advance EO-1022, a potential treatment for patients with HER3-expressing solid breast cancer tumors while beginning a process to evaluate strategic options to maximize shareholder value.</p><p>Shares of the company fell more than 24% in recent premarket activity.</p><p>Price: 0.3489, Change: -0.122, Percent Change: -24.69</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-20 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Elevation Oncology (ELEV) said Thursday it is dropping its development of EO-3021, an antibody-drug conjugate for the potential treatment of advanced, unresectable, or metastatic gastric and gastroesophageal junction cancers.</p><p>The decision to discontinue clinical development of EO-3021 was based on data from the dose escalation and expansion stages of a phase 1 trial which \"deeply disappointed\" the company, said Joseph Ferra, president and chief executive officer.</p><p>The company said it will continue to advance EO-1022, a potential treatment for patients with HER3-expressing solid breast cancer tumors while beginning a process to evaluate strategic options to maximize shareholder value.</p><p>Shares of the company fell more than 24% in recent premarket activity.</p><p>Price: 0.3489, Change: -0.122, Percent Change: -24.69</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520456980","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520456980","pubTimestamp":1742474209,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Elevation Oncology  said Thursday it is dropping its development of EO-3021, an antibody-drug conjugate for the potential treatment of advanced, unresectable, or metastatic gastric and gastroesophageal junction cancers.The decision to discontinue clinical development of EO-3021 was based on data from the dose escalation and expansion stages of a phase 1 trial which \"deeply disappointed\" the company, said Joseph Ferra, president and chief executive officer.The company said it will continue to advance EO-1022, a potential treatment for patients with HER3-expressing solid breast cancer tumors while beginning a process to evaluate strategic options to maximize shareholder value.Shares of the company fell more than 24% in recent premarket activity.Price: 0.3489, Change: -0.122, Percent Change: -24.69","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","ELEV":"Elevation Oncology, Inc."},"translate_title":"Elevation Oncology放弃潜在的转移性癌症药物，评估战略选择；盘前股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELEV":1},"content_text":"Elevation Oncology (ELEV) said Thursday it is dropping its development of EO-3021, an antibody-drug conjugate for the potential treatment of advanced, unresectable, or metastatic gastric and gastroesophageal junction cancers.The decision to discontinue clinical development of EO-3021 was based on data from the dose escalation and expansion stages of a phase 1 trial which \"deeply disappointed\" the company, said Joseph Ferra, president and chief executive officer.The company said it will continue to advance EO-1022, a potential treatment for patients with HER3-expressing solid breast cancer tumors while beginning a process to evaluate strategic options to maximize shareholder value.Shares of the company fell more than 24% in recent premarket activity.Price: 0.3489, Change: -0.122, Percent Change: -24.69","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}